Brief: Bergenbio: Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients

Oncoinvent ASA

19/04/2021 06:06

April 19 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * BERGENBIO ANNOUNCES UPDATE FROM INVESTIGATIONAL PHASE II
TRIALS ASSESSING BEMCENTINIB IN HOSPITALISED COVID-19 PATIENTS
    * DATA RECEIPT IS ONGOING AND EVALUATION OF EFFICACY DATA IS
UNDERWAY
    * EXPLORATORY ANALYSES ARE LOOKING TO DEFINE SUBSETS OF
PATIENTS
WITH BASELINE MARKERS INDICATIVE OF INCREASED DISEASE SEVERITY
WITH POTENTIAL FOR GREATER BENEFIT
    * BEMCENTINIB WAS WELL TOLERATED THROUGHOUT BOTH STUDIES
    * MORE DETAILED TOP LINE DATA EXPECTED TO REPORT IN MAY
    * IN ACCORD2 STUDY THERE WAS NUMERICALLY LOWER NUMBER OF
DEATHS UP
TO DAY 29 IN BEMCENTINIB ARM; IN BGBC020 IT WAS 2 VERSUS 3
RESPECTIVELY

Source text for Eikon:  ID:nWkr1ckBJJ 
Further company coverage:  BGBIO.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))